IGC Pharma Reports Third-Quarter 2026 Results and Business Update
The company says CALMA randomized 170 participants; topline results are expected after last patient-last dose, database lock and unblinding.
CALMA randomized 170 participants; topline results expected following last patient- last dose, database lock and unblindingPOTOMAC, MD / / November 9, 2026 / IGC Pharma, Inc. AMEX:IGC ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational…